202 related articles for article (PubMed ID: 26220655)
1. Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report.
Neyra JA; Rocha NA; Bhargava R; Vaidya OU; Hendricks AR; Rodan AR
BMC Nephrol; 2015 Jul; 16():118. PubMed ID: 26220655
[TBL] [Abstract][Full Text] [Related]
2. Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature.
Dineen M; Hansen E; Guancial E; Sievert L; Sahasrabudhe D
J Oncol Pharm Pract; 2018 Jun; 24(4):314-318. PubMed ID: 28355968
[TBL] [Abstract][Full Text] [Related]
3. Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature.
Ould-Nana I; Cillis M; Gizzi M; Gillion V; Hantson P; Gérard L
J Oncol Pharm Pract; 2021 Jan; 27(1):216-219. PubMed ID: 32397905
[TBL] [Abstract][Full Text] [Related]
4. Abiraterone-induced rhabdomyolysis: A case report.
Moore DC; Moore A
J Oncol Pharm Pract; 2017 Mar; 23(2):148-151. PubMed ID: 26637407
[TBL] [Abstract][Full Text] [Related]
5. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis.
Karakurt Eryılmaz M; Karaağaç M
J Oncol Pharm Pract; 2019 Dec; 25(8):2031-2034. PubMed ID: 31694496
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin-related rhabdomyolysis causing severe proximal paraparesis and acute kidney injury.
Hussain K; Xavier A
BMJ Case Rep; 2019 Oct; 12(10):. PubMed ID: 31601550
[TBL] [Abstract][Full Text] [Related]
8. [Study on the therapy of castration-resistant prostate cancer: randomized phase II study of abiraterone acetate plus LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naïve castration-resistant prostate cancer [SPARE - AP 67/11 of the Association of Urogenital Oncology (AUO)]].
Rexer H
Urologe A; 2014 Nov; 53(11):1665-7. PubMed ID: 25297491
[No Abstract] [Full Text] [Related]
9. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
10. Statin-Induced Rhabdomyolysis Due to Pharmacokinetic Changes From Biliary Obstruction in a Patient With Metastatic Prostate Cancer.
Desikan SP; Sobash P; Fisher A; Desikan R
J Investig Med High Impact Case Rep; 2020; 8():2324709620947275. PubMed ID: 32755252
[TBL] [Abstract][Full Text] [Related]
11. Rhabdomyolysis-induced acute kidney injury in a patient with undifferentiated connective tissue disease: A case report and literature review rhabdomyolysis-induced AKI in a patient with UCTD.
Mai H; Zhao Y; Salerno S; Li Y; Yang L; Fu P
Medicine (Baltimore); 2019 Jul; 98(30):e16492. PubMed ID: 31348259
[TBL] [Abstract][Full Text] [Related]
12. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
[TBL] [Abstract][Full Text] [Related]
13. Multidisciplinary consensus: a practical guide for the integration of abiraterone into clinical practice.
Woo HH; Begbie S; Gogna K; Mainwaring PN; Murphy DG; Parnis F; Steer C; Davis ID
Asia Pac J Clin Oncol; 2014 Sep; 10(3):228-36. PubMed ID: 25132163
[TBL] [Abstract][Full Text] [Related]
14. Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥ 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer.
Petrioli R; Francini E; Fiaschi AI; Laera L; Miano ST; De Rubertis G; Roviello G
Anticancer Res; 2015 May; 35(5):3097-102. PubMed ID: 25964601
[TBL] [Abstract][Full Text] [Related]
15. Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.
Autio KA; Farooki A; Glezerman IG; Chan A; Schneider CW; Barr HC; Seyboth BM; Kampel LJ; Danila DC; Rathkopf DE; Slovin SF; Scher HI; Morris MJ
Clin Genitourin Cancer; 2015 Aug; 13(4):e305-e309. PubMed ID: 25559408
[No Abstract] [Full Text] [Related]
16. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
[TBL] [Abstract][Full Text] [Related]
17. Statins for the prevention of contrast-induced acute kidney injury.
Ball T; McCullough PA
Nephron Clin Pract; 2014; 127(1-4):165-71. PubMed ID: 25343843
[TBL] [Abstract][Full Text] [Related]
18. A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone.
Manokumar T; Aziz S; Breunis H; Rizvi SF; Joshua AM; Tannock IF; Alibhai SM
J Geriatr Oncol; 2016 Mar; 7(2):81-9. PubMed ID: 26853769
[TBL] [Abstract][Full Text] [Related]
19. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
Kluetz PG; Ning YM; Maher VE; Zhang L; Tang S; Ghosh D; Aziz R; Palmby T; Pfuma E; Zirkelbach JF; Mehrotra N; Tilley A; Sridhara R; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2013 Dec; 19(24):6650-6. PubMed ID: 24150234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
